Prithviraj Bose, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, sheds light on a Phase I trial (NCT05714072) evaluating the safety of ruxolitinib in combination with the CDK4/6 inhibitor abemaciclib in patients with myelofibrosis (MF) for patients with a suboptimal response to ruxolitinib monotherapy. Preclinical studies have shown synergistic activity between abemaciclib and ruxolitinib. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть